GlassScriptPhysician profile
Kunjal Patel
NPI 1487918637
$1,982.02
in general payments reported to CMS, 2019-2025
20 companies · $541 in 2025
The $541 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $50.67 · 2022: $144 · 2023: $577 · 2024: $669 · 2025: $541.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,787.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,787.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $745.14 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Abbott Laboratories | $219.21 | 2023-2024 | Jot Dx, Freestyle Libre 3 |
| Lilly USA, LLC | $168.55 | 2023-2025 | Mounjaro, Zepbound, Kisunla |
| Kerecis Limited | $151.67 | 2023-2024 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Abbvie INC. | $135.17 | 2023-2025 | |
| Exact Sciences Corporation | $129.40 | 2023-2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $93.11 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $72.28 | 2024-2025 | Caplyta |
| Pfizer INC. | $47.08 | 2024-2025 | |
| Amgen INC. | $33.23 | 2025 | Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.43 | 2023-2024 | Jardiance, Tradjenta |
| Glaxosmithkline, LLC. | $26.99 | 2019 | |
| Medtronic USA, INC. | $23.68 | 2019 | |
| Genzyme Corporation | $17.15 | 2025 | |
| Ars Pharmaceuticals Operations, INC. | $16.33 | 2025 | Neffy |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $15.88 | 2024 | Teriparatide |
| Otsuka America Pharmaceutical, INC. | $15.26 | 2025 | Rexulti |
| Merck Sharp & Dohme LLC | $14.29 | 2024 | Gardasil, Vaxelis, Vaqta |
| Bausch Health US, LLC | $13.78 | 2025 | Wellbutrin |
| Phathom Pharmaceuticals, INC. | $13.39 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kunjal Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.